{{ text }}
{{ links }}
";s:4:"text";s:16555:"The average salary for Investor Relations Manager at companies like VARIAN MEDICAL SYSTEMS INC in the United States is $145,988 as of December 27, 2021, but the range typically falls between $117,383 and $165,695. [8][9], Varian was founded in 1948 as Varian Associates by Russell H. Varian, Sigurd F. Varian, William Webster Hansen, and Edward Ginzton to sell the Klystron, the first tube which could generate electromagnetic waves at microwave frequencies, and other electromagnetic equipment. On September 16, 2019, during the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian announced Ethos therapy, an artificial intelligence (AI)-driven holistic solution[buzzword] designed to increase the capability, flexibility and efficiency of radiotherapy. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer. [12][13], In August 2020, Siemens Healthineers AG announced that it plans to acquire Varian Medical Systems in an all-stock deal valued at $16.4 billion. [30] The first cancer centers to use the new system were the Champalimaud Foundation in Lisbon, Portugal and Henry Ford Health System in Detroit, Michigan. This site uses cookies and related technologies, as described in our . Varian Medical Systems Inc CIK: 203527 Ticker: VAR Investor Relations Contact Anshul Maheshwari Vice President, Treasury and Investor Relations +1 (650) 424-5163 investors@varian.com Press Contact Kathy Conner Vice President, Global Corporate Marketing +1 (650) 424-5695 kathy.conner@varian.com FOR IMMEDIATE RELEASE Varian Medical Systems Inc. Ticker VAR Exchange NYSE More Industry Medical Appliances & Equipment More Sector Healthcare More 5001-10,000 Employees Based in Palo Alto, California Varian Medical Systems, Inc. designs, manufactures, sells, and services equipment and software products for treating cancer; and x-ray products worldwide. Gains and losses on equity investments:We may incur gains and losses from the sale of our equity investments in privately-held companies. We provide information on topics such as financial results, the development of Siemens Healthineers and financial events. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. We pioneer breakthroughs in healthcare. Total service revenues increased inRead more, Cash, Cash Equivalents and RestrictedRead more, Selling, general and administrative expensesRead more, Approximately half of Oncology SystemsRead more, Acquisition-related expenses and in-process R&DRead more, Based on regional machine utilizationRead more, In addition, government programs thatRead more, Loss Contingencies From time toRead more, Revenues across all regions wereRead more, While we believe that improvedRead more, The EMEA region revenues decreasedRead more, Our long-term growth and valueRead more, If treatment volumes decline materiallyRead more, In fiscal year 2020, OncologyRead more, Other category gross margin percentageRead more, The Americas region revenues wereRead more, We expect that fluctuations ofRead more, We have entered into indemnificationRead more, Goodwill, Intangible Assets and ImpairmentRead more, The $40.5 million impairment chargeRead more, In addition, we use assumptions,Read more, Oncology Systems service revenues wereRead more, Total service revenues in OncologyRead more, Oncology Systems service revenues, whichRead more, The sequential improvement in revenuesRead more, The EMEA region revenues fromRead more, The amount accrued represents estimatesRead more, Changes in estimates of totalRead more, Net Earnings Per Diluted ShareRead more, Oncology Systems gross orders areRead more, During fiscal year 2019, cashRead more, Proton Solutions Revenues Proton SolutionsRead more, Our accrued environmental costs representRead more, The trailing 12 months' growthRead more, Currency fluctuations had a $11.7Read more, Inventories Our inventories include technologyRead more, Warranty Obligations We warrant mostRead more, Borrowings under our credit facilitiesRead more, Total Revenues Total product revenuesRead more, The $18.7 million in restructuringRead more, While our capital allocation prioritiesRead more, Although proton therapy has beenRead more, APAC Oncology Systems revenues decreasedRead more, Reimbursement rates in the UnitedRead more, Impairment of Investments and NotesRead more, (4)As further described in NoteRead more, Such accounting policies require usRead more, In circumstances in which theRead more, The quantitative assessment compares theRead more, Impairment charges in fiscal yearRead more, The dividend yield assumption isRead more, The outstanding instruments were approximatelyRead more, We are investing resources toRead more, Service revenues increased across allRead more, We expect our capital expenditures,Read more, Interest expense increased in fiscalRead more, Business Combinations We allocate theRead more, Varian Medical Systems Inc provided additional information to their SEC Filing as exhibits, Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not, Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news, Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q, Remove data columns and navigations in order to see much more filing content and tables in one view, Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q, Export Annual and Quarterly Reports to Adobe Acrobat (PDF), Microsoft Word (DOCX), Excel (XLSX) and Comma-Delimited (CSV) files for offline viewing, annotations and analysis, Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity, See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years, Use our calculated cost dollar values to discover when and how much registered owners BUY, SELL or excercise their company stock OPTIONS aggregated from Form 4 Insider Transactions SEC Filings, View which hedge funds, pension / retirement funds, endowments, banks and insurance companies have increased or decreased their positions in a particular stock. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers generated revenue of 14.5 billion and adjusted EBIT of 2.2 billion. Varian Medical Systems Inc . [27], Varian manufactures a range of megavoltage LINACs with varying levels of features and complexity, for example different numbers of multileaf collimators or the ability to perform radiosurgery. [citation needed]. Emmaus is a commercial stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies . In addition, these measures may be different from non-GAAP measures used by other companies, limiting their usefulness for comparison purposes. We exclude such gains and losses because we do not believe they are reflective of our core business. "articleDate": "January 30, 2017", These supplemental financial measures may have limitations as analytical tools and should not be viewed in isolation or as alternatives to measures of Siemens Healthineers net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework in its half-year consolidated financial statements and consolidated financial statements. The corporate rate reduction resulted in a remeasurement of our deferred tax assets of $1.4 million in the fourth quarter and $43.2 million in fiscal year 2018. The system features unique dual-layer MLC that enables high modulation with low leakage for every field or arc. We have provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. Non-GAAP operating earnings and non-GAAP net earnings exclude the following items, except for gain and losses on equity investments, and significant non-recurring tax expense or benefit, which are only excluded from non-GAAP net earnings: Amortization of intangible assets and amortization of inventory step-up:We do not acquire businesses and assets on a predictable cycle. By their nature, such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Siemens Healthineers to be materially different from results, performance or achievements expressed or implied by such forward-looking statements. About Varian Medical Systems Varian Medical Systems focuses energy on saving lives and is the world's leading manufacturer of medical devices and software for treating and managing cancer. Mit Ihrer Anmeldung erklren Sie sich damit einverstanden, Inhalte von uns zu erhalten. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. You are urged to consider these factors carefully in evaluating the forward-looking statements in this announcement and not to place undue reliance on such statements. Nevertheless, automation in both quality assurance and clinical operation generally make the LINAC easier to operate by checkers and radiation therapists. We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. Such risks and uncertainties include our ability to achieve expected synergies from acquisitions; risks associated with integrating recent acquisitions; global economic conditions and changes to trends for cancer treatment regionally; currency exchange rates and tax rates; the impact of the Tax Cuts and Jobs Act; the impact of the Affordable Health Care for America Act (including excise taxes on medical devices) and any further healthcare reforms (including changes to Medicare and Medicaid), and/or changes in third-party reimbursement levels; recent and potential future tariffs or a global trade war; demand for and delays in delivery of the company's products; the company's ability to develop, commercialize and deploy new products; the company's ability to meet Food and Drug Administration (FDA) and other regulatory requirements, regulations or procedures; changes in regulatory environments; risks associated with the company providing financing for the construction and start-up operations of particle therapy centers, challenges associated with commercializing the company's proton solutions business; challenges to public tender awards and the loss of such awards or other orders; the effect of adverse publicity; the company's reliance on sole or limited-source suppliers; the company's ability to maintain or increase margins; the impact of competitive products and pricing; the potential loss of key distributors or key personnel; challenges related to entering into new business lines; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. Since then, he has built a robust investor relations strategy and enhanced the company's financial planning and business partnership functions. "articleDate": "October 23, 2019", Operating earnings for the segment increased 3% for the quarter and were flat for the full year. In connection with the separation, Varian received a $200 million cash payment from Varex. We exclude such expenses or benefits as they are related to acquisitions and have no direct correlation to the operation of our on-going business. [citation needed]. Our fiscal year 2020 guidance considers the recently announced tariff exclusions from both China and the United States Trade Representative. En vous inscrivant la newsletter, vous consentez la rception de contenus de notre part. PALO ALTO, Calif., Jan. 30, 2017 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) today announced it has successfully completed the separation of its Imaging Components Business, which is now established as Varex Imaging Corporation (NASDAQ: VREX). Impairment charges:We incur impairment charges that result from events, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our on-going business. This press release includes the following non-GAAP financial measures derived from our Condensed Consolidated Statements of Earnings: non-GAAP operating earnings, non-GAAP net earnings and non-GAAP net earnings per diluted share. Discover the stories of pioneers pushing the boundaries of whats possible in healthcare to help improve peoples lives around the world. We believe that excluding amortization of intangible assets and amortization of inventory step-up allows the users of our financial statements to better review and understand the historic and current results of our operations, and also facilitates comparisons to peer companies. Download the Document. [33] These are an all pencil-beam scanning proton therapy system utilizing IMPT (intensity modulated proton therapy), which was developed with PSI of Switzerland. , , , , , , Environmental, Social and Governance (ESG), HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. To access the call via telephone, dial 1-877-869-3847 from inside the U.S. or 1-201-689-8261 from outside the U.S. Represents the tax effect of a change in law related to the U.S. Tax Cuts and Jobs Act. The meeting will be held at The Resort at Pelican Hill, 22701 Pelican Hill Road South . Significant litigation charges or benefits and legal costs: We may incur charges or benefits as well as legal costs from time to time related to litigation and other contingencies. PALO ALTO, Calif., Oct. 23, 2019 /PRNewswire/ --, New President of Interventional Oncology and New Chief Financial Officer. Such forward-looking statements are based on numerous assumptions regarding Siemens Healthineers present and future business strategies and the market environment in which Siemens Healthineers will operate in the future. AvalonBay Communities, Inc. (NYSE: AVB) announced today that its 2015 Annual Meeting of Stockholders will be held on Thursday, May 21, 2015 at 9:00 A.M. local time. "title": "Varian Reports Results for Fourth Quarter and Full Fiscal Year 2019; Appoints New President of Interventional Oncology Solutions and New Chief Financial Officer", About Varian. In addition, this measure may be different from non-GAAP measures used by other companies, limiting its usefulness for comparison purposes. The non-GAAP financial measures should not be considered in isolation from measures of financial performance prepared in accordance with GAAP. This is primarily done by automating several functions typically performed manually by radiographers, such as switching between treatment beams automatically. Everywhere. The number of bullish hedge fund bets . Varian Medical Systems in Las Vegas, reviews by real people. We exclude these charges or benefits, when significant, as well as legal costs associated with significant legal matters, because we do not believe they are reflective of on-going business and operating results. At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. Cash Flows from operations were $372 million for the fiscal year, down 18% due to higher working capital to support product transition and growth. ";s:7:"keyword";s:41:"varian medical systems investor relations";s:5:"links";s:419:"Lou Malnati's Vs Gino's East Vs Giordano's,
Knwa Anchor Leaves,
Taylor Mcwilliams Parents,
Articles V
";s:7:"expired";i:-1;}